Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Current Valuation Ratios
| Zoetis Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | Health Care | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||
| Current share price (P) | $167.23 | |||||||||||||||||
| No. shares of common stock outstanding | 456,295,137 | |||||||||||||||||
| Growth rate (g) | 35.45% | |||||||||||||||||
| Earnings per share (EPS) | $5.14 | |||||||||||||||||
| Next year expected EPS | $6.96 | |||||||||||||||||
| Operating profit per share | $6.61 | |||||||||||||||||
| Sales per share | $18.72 | |||||||||||||||||
| Book value per share (BVPS) | $10.95 | |||||||||||||||||
| Valuation Ratios (Price Multiples) | ||||||||||||||||||
| Price to earnings (P/E) | 32.55 | 119.59 | 32.34 | 17.88 | 44.80 | 64.24 | 24.41 | 23.91 | 19.55 | 22.00 | 22.35 | 38.60 | 34.03 | 49.03 | 40.92 | |||
| Price to next year expected earnings | 24.03 | 648.27 | 23.98 | 16.29 | 41.31 | 49.29 | 33.56 | 21.05 | — | 23.80 | 19.00 | 34.05 | 29.00 | 43.65 | 36.52 | |||
| Price-earnings-growth (PEG) | 0.92 | — | 0.93 | 1.83 | 5.30 | 2.12 | — | 1.76 | — | — | 1.27 | 2.89 | 1.96 | 3.98 | 3.39 | |||
| Price to operating profit (P/OP) | 25.30 | 33.53 | 27.46 | 12.61 | 34.52 | 50.41 | 20.73 | 25.34 | 16.82 | 12.00 | 28.14 | 33.40 | 32.24 | 48.85 | 36.73 | |||
| Price to sales (P/S) | 8.93 | 8.26 | 7.09 | 2.62 | 6.59 | 20.34 | 7.18 | 6.80 | 5.49 | 2.73 | 7.02 | 5.81 | 11.21 | 8.80 | 4.70 | |||
| Price to book value (P/BV) | 15.27 | — | 28.80 | 6.83 | 3.08 | 49.97 | 9.15 | 7.86 | 6.78 | 1.98 | 3.22 | 4.84 | 7.21 | 10.12 | 7.94 | |||
Based on: 10-K (reporting date: 2023-12-31).
If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.
Historical Valuation Ratios (Summary)
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
An analysis of the valuation multiples from 2019 to 2023 reveals a general trend of multiple compression across all measured metrics. While valuation levels experienced moderate growth or stability between 2019 and 2021, a notable contraction occurred starting in 2022, suggesting a market re-rating of the asset's value relative to its financial performance.
- Price to Earnings (P/E) Ratio
- The P/E ratio peaked in 2020 at 48.25 before entering a period of steady decline. By December 31, 2023, the ratio had fallen to 35.84, representing a significant reduction in the premium investors were willing to pay for each dollar of earnings compared to the 2019-2021 period.
- Price to Operating Profit (P/OP) Ratio
- Operating profit multiples remained relatively stable between 2019 and 2021, ranging from 33.82 to 35.22. A sharp contraction was observed in 2022, where the ratio dropped to 27.31, followed by a marginal stabilization at 27.86 in 2023.
- Price to Sales (P/S) Ratio
- The P/S ratio followed an upward trajectory through 2021, reaching a peak of 12.00. Subsequently, the ratio corrected downward, falling below the 10.00 threshold in 2022 and remaining nearly flat at 9.83 by the end of 2023.
- Price to Book Value (P/BV) Ratio
- The P/BV ratio exhibited a consistent and uninterrupted downward trend throughout the five-year period. The ratio declined from 25.42 in 2019 to 16.81 in 2023, indicating a steady reduction in the market price premium relative to the equity book value.
The synchronized decline in P/E, P/OP, and P/S ratios starting in 2022 indicates a systemic shift in valuation sentiment. The most pronounced and linear trend is the erosion of the P/BV ratio, which suggests that while market valuations remain high relative to book value, the magnitude of that premium has diminished consistently over the analyzed timeframe.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Earnings (P/E)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 457,867,115 | 463,386,716 | 471,970,580 | 475,166,373 | 474,933,945 | |
| Selected Financial Data (US$) | ||||||
| Net income attributable to Zoetis Inc. (in millions) | 2,344) | 2,114) | 2,037) | 1,638) | 1,500) | |
| Earnings per share (EPS)2 | 5.12 | 4.56 | 4.32 | 3.45 | 3.16 | |
| Share price1, 3 | 183.49 | 171.90 | 197.76 | 166.32 | 144.94 | |
| Valuation Ratio | ||||||
| P/E ratio4 | 35.84 | 37.68 | 45.82 | 48.25 | 45.89 | |
| Benchmarks | ||||||
| P/E Ratio, Competitors5 | ||||||
| AbbVie Inc. | 63.84 | 22.62 | 22.07 | — | — | |
| Amgen Inc. | 23.14 | 19.56 | 21.05 | — | — | |
| Bristol-Myers Squibb Co. | 12.27 | 23.97 | 20.92 | — | — | |
| Danaher Corp. | 39.09 | 25.65 | 29.94 | — | — | |
| Eli Lilly & Co. | 135.24 | 50.08 | 40.66 | — | — | |
| Gilead Sciences Inc. | 16.17 | 22.68 | 12.36 | — | — | |
| Johnson & Johnson | 10.73 | 22.97 | 20.93 | — | — | |
| Merck & Co. Inc. | 893.99 | 19.21 | 14.78 | — | — | |
| Pfizer Inc. | 73.42 | 7.58 | 11.76 | — | — | |
| Regeneron Pharmaceuticals Inc. | 25.99 | 19.68 | 8.37 | — | — | |
| Thermo Fisher Scientific Inc. | 35.65 | 30.55 | 27.35 | — | — | |
| Vertex Pharmaceuticals Inc. | 30.42 | 23.02 | 26.55 | — | — | |
| P/E Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 32.80 | 20.23 | 19.27 | — | — | |
| P/E Ratio, Industry | ||||||
| Health Care | 30.62 | 21.22 | 21.55 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 Data adjusted for splits and stock dividends.
2 2023 Calculation
EPS = Net income attributable to Zoetis Inc. ÷ No. shares of common stock outstanding
= 2,344,000,000 ÷ 457,867,115 = 5.12
3 Closing price as at the filing date of Zoetis Inc. Annual Report.
4 2023 Calculation
P/E ratio = Share price ÷ EPS
= 183.49 ÷ 5.12 = 35.84
5 Click competitor name to see calculations.
An analysis of the financial metrics from 2019 to 2023 reveals a divergence between consistent earnings growth and the market's valuation multiple. While the company demonstrated a steady increase in profitability, the price-to-earnings ratio experienced a notable contraction, particularly following 2021.
- Earnings per share (EPS) trends
- A consistent upward trajectory is observed in EPS, which grew annually from 3.16 USD in 2019 to 5.12 USD in 2023. This represents uninterrupted growth in bottom-line profitability over the five-year period.
- Share price fluctuations
- The share price exhibited a general increase from 2019 to 2021, peaking at 197.76 USD. This was followed by a decline to 171.90 USD in 2022 and a moderate recovery to 183.49 USD by the end of 2023.
- Price-to-Earnings (P/E) ratio compression
- The P/E ratio reached a high of 48.25 in 2020 before entering a period of steady decline, reaching 35.84 by 2023. This compression indicates that while earnings grew, the market's willingness to pay a premium for those earnings decreased.
- Valuation synthesis
- The combination of rising EPS and a falling P/E ratio suggests that the reduction in the share price after 2021 was driven more by a contraction in the valuation multiple than by a decline in operational performance. The stock transitioned from a high-growth valuation peak in 2020 to a more conservative multiple by 2023, despite the company achieving its highest earnings levels in the final year of the period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Operating Profit (P/OP)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 457,867,115 | 463,386,716 | 471,970,580 | 475,166,373 | 474,933,945 | |
| Selected Financial Data (US$) | ||||||
| Operating income (in millions) | 3,016) | 2,917) | 2,760) | 2,244) | 1,967) | |
| Operating profit per share2 | 6.59 | 6.29 | 5.85 | 4.72 | 4.14 | |
| Share price1, 3 | 183.49 | 171.90 | 197.76 | 166.32 | 144.94 | |
| Valuation Ratio | ||||||
| P/OP ratio4 | 27.86 | 27.31 | 33.82 | 35.22 | 35.00 | |
| Benchmarks | ||||||
| P/OP Ratio, Competitors5 | ||||||
| AbbVie Inc. | 24.34 | 14.78 | 14.21 | — | — | |
| Amgen Inc. | 19.69 | 13.40 | 16.24 | — | — | |
| Bristol-Myers Squibb Co. | 13.53 | 18.29 | 19.84 | — | — | |
| Danaher Corp. | 35.64 | 20.97 | 25.14 | — | — | |
| Eli Lilly & Co. | 109.75 | 43.88 | 35.70 | — | — | |
| Gilead Sciences Inc. | 12.05 | 14.21 | 7.76 | — | — | |
| Johnson & Johnson | 17.78 | 17.62 | 18.68 | — | — | |
| Merck & Co. Inc. | 138.56 | 15.55 | 15.39 | — | — | |
| Pfizer Inc. | 121.63 | 6.64 | 12.74 | — | — | |
| Regeneron Pharmaceuticals Inc. | 25.39 | 18.01 | 7.55 | — | — | |
| Thermo Fisher Scientific Inc. | 31.16 | 25.30 | 21.07 | — | — | |
| Vertex Pharmaceuticals Inc. | 28.74 | 17.75 | 22.35 | — | — | |
| P/OP Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 32.68 | 15.94 | 16.68 | — | — | |
| P/OP Ratio, Industry | ||||||
| Health Care | 27.48 | 16.58 | 18.20 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 Data adjusted for splits and stock dividends.
2 2023 Calculation
Operating profit per share = Operating income ÷ No. shares of common stock outstanding
= 3,016,000,000 ÷ 457,867,115 = 6.59
3 Closing price as at the filing date of Zoetis Inc. Annual Report.
4 2023 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 183.49 ÷ 6.59 = 27.86
5 Click competitor name to see calculations.
The analysis of valuation multiples from 2019 to 2023 reveals a divergence between operational growth and market valuation. While operational efficiency has improved consistently, the market's willingness to pay a premium for those earnings has contracted over the observed period.
- Operating Profit Performance
- Operating profit per share exhibited a consistent upward trajectory, increasing annually from 4.14 US$ in 2019 to 6.59 US$ in 2023. This steady growth indicates a sustained improvement in core operational profitability regardless of share price fluctuations.
- Share Price Volatility
- The share price experienced an initial growth phase, peaking at 197.76 US$ in 2021. A correction followed in 2022, with the price dropping to 171.90 US$, before a partial recovery to 183.49 US$ by the end of 2023.
- Price to Operating Profit (P/OP) Dynamics
- The P/OP ratio remained relatively stable and elevated between 33.82 and 35.22 from 2019 through 2021. A significant compression of the multiple occurred in 2022, where the ratio decreased to 27.31. Despite the continued rise in operating profit per share in 2023, the ratio remained at a lower plateau of 27.86, indicating that the market valuation of operating profits has shifted to a lower baseline compared to the 2019-2021 period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Sales (P/S)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 457,867,115 | 463,386,716 | 471,970,580 | 475,166,373 | 474,933,945 | |
| Selected Financial Data (US$) | ||||||
| Revenue (in millions) | 8,544) | 8,080) | 7,776) | 6,675) | 6,260) | |
| Sales per share2 | 18.66 | 17.44 | 16.48 | 14.05 | 13.18 | |
| Share price1, 3 | 183.49 | 171.90 | 197.76 | 166.32 | 144.94 | |
| Valuation Ratio | ||||||
| P/S ratio4 | 9.83 | 9.86 | 12.00 | 11.84 | 11.00 | |
| Benchmarks | ||||||
| P/S Ratio, Competitors5 | ||||||
| AbbVie Inc. | 5.72 | 4.61 | 4.53 | — | — | |
| Amgen Inc. | 5.78 | 5.17 | 5.10 | — | — | |
| Bristol-Myers Squibb Co. | 2.19 | 3.29 | 3.16 | — | — | |
| Danaher Corp. | 7.76 | 5.79 | 6.37 | — | — | |
| Eli Lilly & Co. | 20.77 | 10.96 | 8.01 | — | — | |
| Gilead Sciences Inc. | 3.40 | 3.86 | 2.85 | — | — | |
| Johnson & Johnson | 4.43 | 4.34 | 4.66 | — | — | |
| Merck & Co. Inc. | 5.43 | 4.71 | 3.96 | — | — | |
| Pfizer Inc. | 2.61 | 2.35 | 3.15 | — | — | |
| Regeneron Pharmaceuticals Inc. | 7.84 | 7.01 | 4.20 | — | — | |
| Thermo Fisher Scientific Inc. | 4.99 | 4.73 | 5.39 | — | — | |
| Vertex Pharmaceuticals Inc. | 11.16 | 8.56 | 8.21 | — | — | |
| P/S Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 5.89 | 4.56 | 4.50 | — | — | |
| P/S Ratio, Industry | ||||||
| Health Care | 3.52 | 3.11 | 3.28 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 Data adjusted for splits and stock dividends.
2 2023 Calculation
Sales per share = Revenue ÷ No. shares of common stock outstanding
= 8,544,000,000 ÷ 457,867,115 = 18.66
3 Closing price as at the filing date of Zoetis Inc. Annual Report.
4 2023 Calculation
P/S ratio = Share price ÷ Sales per share
= 183.49 ÷ 18.66 = 9.83
5 Click competitor name to see calculations.
The financial trajectory from 2019 to 2023 reveals a divergence between consistent revenue growth and fluctuating market valuation. While top-line performance per share exhibited an uninterrupted upward trend, the market multiple applied to those sales experienced a cycle of expansion followed by a notable contraction.
- Sales per Share Performance
- A steady and consistent increase in sales per share is observed throughout the analyzed period. The value rose from 13.18 US$ in 2019 to 18.66 US$ by the end of 2023, indicating a persistent growth in revenue generation capability on a per-share basis.
- Share Price Trends
- The share price experienced an upward trajectory from 2019, peaking at 197.76 US$ in 2021. This was followed by a decline to 171.90 US$ in 2022 and a partial recovery to 183.49 US$ in 2023. The price volatility in the latter half of the period contrasts with the linear growth seen in sales.
- Price-to-Sales (P/S) Ratio Analysis
- The P/S ratio expanded from 11.00 in 2019 to a peak of 12.00 in 2021, suggesting a period of valuation expansion where the share price grew faster than sales. A significant contraction occurred in 2022, with the ratio falling to 9.86, and it remained relatively flat at 9.83 in 2023. This compression indicates that while the company continued to grow its sales, the market reduced the premium attributed to each dollar of revenue generated.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Book Value (P/BV)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 457,867,115 | 463,386,716 | 471,970,580 | 475,166,373 | 474,933,945 | |
| Selected Financial Data (US$) | ||||||
| Total Zoetis Inc. equity (in millions) | 4,997) | 4,405) | 4,543) | 3,769) | 2,708) | |
| Book value per share (BVPS)2 | 10.91 | 9.51 | 9.63 | 7.93 | 5.70 | |
| Share price1, 3 | 183.49 | 171.90 | 197.76 | 166.32 | 144.94 | |
| Valuation Ratio | ||||||
| P/BV ratio4 | 16.81 | 18.08 | 20.55 | 20.97 | 25.42 | |
| Benchmarks | ||||||
| P/BV Ratio, Competitors5 | ||||||
| AbbVie Inc. | 29.97 | 15.52 | 16.53 | — | — | |
| Amgen Inc. | 24.94 | 35.01 | 18.51 | — | — | |
| Bristol-Myers Squibb Co. | 3.35 | 4.88 | 4.07 | — | — | |
| Danaher Corp. | 3.47 | 3.64 | 4.16 | — | — | |
| Eli Lilly & Co. | 65.80 | 29.36 | 25.28 | — | — | |
| Gilead Sciences Inc. | 4.01 | 4.90 | 3.65 | — | — | |
| Johnson & Johnson | 5.48 | 5.37 | 5.90 | — | — | |
| Merck & Co. Inc. | 8.68 | 6.07 | 5.05 | — | — | |
| Pfizer Inc. | 1.75 | 2.48 | 3.35 | — | — | |
| Regeneron Pharmaceuticals Inc. | 3.96 | 3.77 | 3.60 | — | — | |
| Thermo Fisher Scientific Inc. | 4.57 | 4.83 | 5.18 | — | — | |
| Vertex Pharmaceuticals Inc. | 6.26 | 5.50 | 6.16 | — | — | |
| P/BV Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 6.77 | 5.66 | 5.72 | — | — | |
| P/BV Ratio, Industry | ||||||
| Health Care | 5.94 | 5.26 | 5.48 | — | — | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 Data adjusted for splits and stock dividends.
2 2023 Calculation
BVPS = Total Zoetis Inc. equity ÷ No. shares of common stock outstanding
= 4,997,000,000 ÷ 457,867,115 = 10.91
3 Closing price as at the filing date of Zoetis Inc. Annual Report.
4 2023 Calculation
P/BV ratio = Share price ÷ BVPS
= 183.49 ÷ 10.91 = 16.81
5 Click competitor name to see calculations.
A comprehensive analysis of the valuation multiples from 2019 to 2023 reveals a consistent contraction in the Price to Book Value (P/BV) ratio despite a general increase in the underlying book value per share.
- Price to Book Value (P/BV) Trend
- The P/BV ratio exhibited a steady downward trajectory over the five-year period, declining from 25.42 in 2019 to 16.81 by the end of 2023. This trend indicates a significant reduction in the market premium attributed to the company's net assets over the analyzed timeframe.
- Book Value per Share (BVPS) Progression
- The book value per share demonstrated strong growth, increasing from 5.70 in 2019 to 10.91 in 2023. With the exception of a marginal decrease between 2021 and 2022, the BVPS nearly doubled, reflecting a consistent increase in the company's equity base on a per-share basis.
- Share Price Dynamics
- The share price experienced fluctuation, reaching a peak of 197.76 in 2021 before declining to 171.90 in 2022 and recovering to 183.49 by the end of 2023. The volatility of the market price, when juxtaposed with the steadily rising book value, accelerated the compression of the P/BV multiple.
The divergence between the rising book value and the falling P/BV ratio suggests a valuation re-rating. While the intrinsic accounting value per share has grown substantially, the market is applying a lower multiple to that value, suggesting that the stock is being valued more conservatively relative to its book value than in previous years.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?